文献速递炎症性肠病

随机临床试验:结肠镜粪菌移植联合万古霉素治疗难治性重症艰难梭菌感染——单次与多次输注的比较

Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
PubMed 文献 · Aliment Pharmacol Ther · 2018-05-30

该随机临床试验纳入56例抗生素难治性重症艰难梭菌感染患者,比较单次粪菌输注联合14天万古霉素方案与多次粪菌输注联合14天万古霉素方案的治愈率。结果显示多次输注组治愈率100%,单次输注组75%,差异有统计学意义(P=0.01),两组均未观察到与治疗方案相关的严重不良事件。

要点

  • 多次粪菌输注联合万古霉素治愈率100%,单次输注联合万古霉素为75%,差异有统计学意义(P=0.01)。
  • 两组均未观察到与治疗方案相关的严重不良事件。
  • 多次输注方案中,所有受试者至少接受两次输注,有假膜性结肠炎者继续输注直至假膜消失。

核心结论

  • 以假膜消失为导向的多次粪菌输注联合万古霉素方案,在治愈抗生素难治性重症艰难梭菌感染方面显著优于单次粪菌移植后联合万古霉素方案。

研究设计与样本

  • 随机临床试验,纳入抗生素难治性重症艰难梭菌感染受试者,随机分配至单次粪菌输注联合14天万古霉素方案组(FMT-S组)或多次粪菌输注联合14天万古霉素方案组(FMT-M组),每组28例,共56例。

主要发现

  • FMT-S组21例治愈,FMT-M组28例治愈(75% vs 100%,符合方案分析和意向性分析结果均相同;P=0.01)。
  • 两组均未观察到与治疗方案相关的严重不良事件。

关键数值与推荐

  • 主要结局为抗生素难治性重症艰难梭菌感染的治愈。
  • FMT-M组所有受试者至少接受两次输注,有假膜性结肠炎者继续输注直至假膜消失。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Faecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridium difficile infection. Far less evidence exists on the efficacy of FMT in treating severe Clostridium difficile infection refractory to antibiotics. AIM: To compare the efficacy of two FMT-based protocols associated with vancomycin in curing subjects with severe Clostridium difficile infection refractory to antibiotics. METHODS: Subjects with severe Clostridium difficile infection refractory to antibiotics were randomly assigned to one of the two following treatment arms: (1) FMT-S, including a single faecal infusion via colonoscopy followed by a 14-day vancomycin course, (2) FMT-M, including multiple faecal infusions plus a 14-day vancomycin course. In the FMT-M group, all subjects received at least two infusions, while those with pseudomembranous colitis underwent further infusions until the disappearance of pseudomembranes. The primary outcome was the cure of refractory severe Clostridium difficile infection. RESULTS: Fifty six subjects, 28 in each treatment arm, were enrolled. Twenty one patients in the FMT-S group and 28 patients in the FMT-M group were cured (75% vs 100%, respectively, both in per protocol and intention-to-treat analyses; P = 0.01). No serious adverse events associated with any of the two treatment protocols were observed. CONCLUSIONS: A pseudomembrane-driven FMT protocol consisting of multiple faecal infusions and concomitant vancomycin was significantly more effective than a single faecal transplant followed by vancomycin in curing severe Clostridium difficile infection refractory to antibiotics. Clinical-Trials.gov registration number: NCT03427229.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. 2018. PMID: 29851107. doi:10.1111/apt.14816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。